Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARGX-124 · 1 trial · 1 indication
AE : adverse event ; SAE : serious adverse event.
| Arm | Type | Description |
|---|---|---|
| ARGX-124 | EXPERIMENTAL | Participants receiving the experimental drug |
| Placebo | PLACEBO_COMPARATOR | Participants receiving placebo |
| Name | Type | Description |
|---|---|---|
| ARGX-124 | BIOLOGICAL | Administrations of ARGX-124 |
| Placebo | OTHER | Administrations of placebo comparator |
Inclusion Criteria: * Is at least the local legal age of consent and aged 18 to 65 years, inclusive, when signing the ICF. * Is a female of Nonchildbearing Potential (postmenopausal or surgically sterilized) or a male. * Has a body weight between 50 and 120 kg and a BMI between 18 and 30.5 kg/m2, i...
ARGX-124 is an investigational monoclonal antibody being studied for use in healthy volunteers. It is currently in Phase 1 clinical development, with a trial assessing its safety in healthy participants. The drug is not yet approved and is still in clinical trials.
ARGX-124 targets the neonatal Fc receptor (FcRn), a protein involved in antibody recycling. By targeting FcRn, the drug may modulate IgG levels, though its exact therapeutic application is still under investigation. This mechanism is being evaluated in early-stage clinical trials.
ARGX-124 is being developed by argenx SE, a biopharmaceutical company listed on the stock exchange under the ticker ARGX. The company is conducting a Phase 1 clinical trial to evaluate the safety of ARGX-124 in healthy volunteers.
ARGX-124 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is designed to assess the safety of ARGX-124 in healthy volunteers.
ARGX-124 is being studied in a Phase 1 clinical trial with the identifier NCT07377396. This randomized, double-blind, placebo-controlled study is recruiting 104 healthy volunteers in Canada to assess the safety of ARGX-124. The trial is currently active and recruiting participants.